Silence Therapeutics PLC Silence Strengthens Board and Leadership Team (0577S)
June 21 2018 - 1:00AM
UK Regulatory
TIDMSLN
RNS Number : 0577S
Silence Therapeutics PLC
21 June 2018
Silence Therapeutics Strengthens Board and Leadership Team
21 June 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces today the appointment of Dave Lemus to its
Board as Non-Executive Director effective immediately. Silence also
announces the appointment of Richard Jenkins as Head of Clinical
Development.
Dave has over 20 years of US and international business
experience in the pharmaceutical and biotechnology industries,
having served in executive management and non-executive board roles
in multiple US and European private and publicly-traded companies.
Dave is currently Executive Vice Chair, Chief Operating Officer and
Chief Financial Officer of Proteros biostructures Gmbh. Prior to
that he served as Interim Chief Financial Officer and Chief
Operating Officer of Medigene AG, a publicly-listed German
biotechnology company focused on the research and development of
T-Cell-Receptor based immunotherapies, and prior to this as Chief
Executive Officer of Sigma Tau Pharmaceuticals, Inc. Dave was Chief
Financial Officer and Executive VP of MorphoSys AG, taking the
Company public in 1999 and held various positions at leading pharma
companies including at Hoffman La Roche.
Dave currently serves as a Non-Executive board member of
BioHealth Innovation, Inc., Sorrento Therapeutics Inc., and the MIT
Club of Washington DC. Dave is a Certified Public Accountant in the
US, and holds a Bachelor of Science degree in Accounting from the
University of Maryland and Master of Science/MBA from the
Massachusetts Institute of Technology (MIT).
Richard Jenkins has over 28 years' experience in clinical
development and drug discovery, and will be heading the clinical
development function as Silence advances its lead asset through the
clinic, reporting directly to Annalisa Jenkins. He has held
numerous leadership positions in big pharma throughout his career.
Richard most recently served as Senior Scientific Director at
Takeda Development Centre (Europe) where he was Global Clinical
Development Team Leader for development of Takeda's upper GI
compounds. Prior to this, Richard spent 17 years at GlaxoSmithKline
Pharmaceuticals in the UK and US in both Clinical Development and
Genetics Discovery Research Portfolio Management. Richard began his
career at Roche. Silence also announces that Torsten Hoffmann has
stepped down as Chief Scientific Officer due to personal
reasons.
Annalisa Jenkins, Executive Chair of Silence Therapeutics,
commented: "I am very pleased to welcome Dave to the Silence Board
of Directors. Dave has joined at a pivotal time for the company.
His successful track record and proven leadership in building and
managing high performance management teams will strengthen our
capabilities as we continue to maximise the potential of our
GalNAc-based SRNi platform. Additionally, Richard Jenkins will
bolster our clinical development expertise as we progress our iron
overload compound into clinical testing."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
Full name and age: David Jakob Lemus (aged 55).
Mr. Lemus does not currently hold any ordinary shares in
Silence.
Current Directorships or Partnerships:
BioHealth Innovation, Inc.
MIT Club of Washington DC
Proteros biostructures GmbH
Sorrento Therapeutics, Inc.
Previous Directorships or Partnerships:
Axela Inc.
Medigene AG
PhRMA
Sigma Tau Pharmaceuticals, Inc.
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
Enquiries:
Silence Therapeutics plc Tel: +44 (0) 20 3457
Annalisa Jenkins, Executive Chair 6900
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0) 20 7418
James Steel/ Oliver Jackson 8900
Media & IR Enquiries Tel: +44 (0) 20 3714
Optimum Strategic Communications 1788
Mary Clark/ Eva Haas/ Hollie Vile
silence@optimumcomms.com
IR Enquiries - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
Silence.Therapeutics@burnsmc.com
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAQBLFLVQFLBBE
(END) Dow Jones Newswires
June 21, 2018 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024